Flexibility and an **AV Fistula Indication**

The Covera™ Vascular Covered Stent is a flexible, self-expanding covered stent uniquely designed to conform to native vessels in challenging AV anatomy.

The AVeNEW Clinical Study is the **first and only active trial** to assess the effectiveness of covered stents in the non-stented venous outflow of patients dialyzing via an AV fistula. Choose the **ONLY** covered stent **INDICATED** for AV fistula use.

78.7%
TLPP vs. 47.9% with PTA Alone

99
Additional average days between interventions



Covera™
Vascular Covered Stent

The AVeNEW Clinical Study was a prospective, multi-center, randomized, concurrently-controlled clinical study of the Covera™ Vascular Covered Stent in the treatment of stenosis in the venous outflow of the AV fistula access circuits. 280 patients were treated with the Covera Vascular Covered Stent at 24 investigational sites in the US, Europe, Australia and New Zealand. Patients were distributed globally with at least 50-75% being treated in the US. Target Lesion Primary Patency (TLPP) of 78.7% vs. 47.9% with PTA alone was defined as the interval following the index intervention until the next clinically-driven reintervention at or adjacent to the original treatment site or until the extremity was abandoned for permanent access. AVeNEW Clinical Study. Data on File. Bard Peripheral Vascular Inc., Tempe AZ

Please consult product labels and instructions for use for indications, contraindications, hazards, warnings and precautions.

crbard.com/peripheral-vascular | bd.com BD, Tempe, AZ, USA, 1 800 321 4254